Diabetes Insulin Dosing Enhanced Through Hedia and Glooko Partnership
Glooko, Inc. and Hedia have launched an innovative interoperable solution designed to improve diabetes management. The solution integrates connected care, remote patient monitoring, and digital therapeutic technologies to provide enhanced support for individuals with Type 1 and Type 2 diabetes who need advanced bolus insulin dosing. Initially available in the United Kingdom, the solution will soon expand to other European countries.
A bolus is an additional dose of insulin taken to manage a rise in blood glucose levels, typically after eating a meal or snack. Generally, to correct high blood sugar, one unit of insulin can reduce blood glucose by 50 mg/dl, though this can vary depending on the individual. For those with diabetes who do not use an insulin pump, calculating the correct bolus dose can be a challenging task for both patients and their healthcare providers (HCPs).
Glooko, a digital health company, has developed a solution to make this process easier and more accurate. The Glooko platform allows patients to seamlessly share their diabetes-related data, such as blood glucose readings, insulin doses, carbohydrate intake, exercise activity, blood pressure, and weight, with their healthcare providers. This solution enhances diabetes management by providing comprehensive insights into a patient’s daily health activities, making it easier to adjust treatment plans and improve health outcomes.
In partnership with Hedia, Glooko is introducing the Hedia Diabetes Assistant, which integrates with its platform to provide personalized insulin dose recommendations. This integration ensures that patients have real-time access to tailored bolus calculations, supporting more effective management of their diabetes. By considering various factors such as active insulin, food intake, physical activity, and blood glucose levels, the Hedia Diabetes Assistant generates insulin recommendations that help stabilize blood glucose levels and simplify diabetes management.
One of the key features of the Glooko-Hedia integration is its ability to assist people who rely on multiple daily injections (MDI) rather than insulin pumps. This solution allows patients who are not using pumps to manage their insulin dosing effectively, providing them with personalized and actionable recommendations. The goal is to reduce the complexity of managing diabetes with multiple daily injections and ensure that patients can maintain consistent blood glucose control.
This partnership also benefits healthcare providers by giving them enhanced visibility into their patients’ health data. With easy access to key metrics such as blood glucose levels, insulin doses, carbohydrate intake, physical activity, and more, providers can make more informed decisions about a patient’s treatment plan. This approach helps streamline care, improve patient outcomes, and boost the efficiency of healthcare providers in both remote and in-person care settings. By allowing healthcare teams to monitor their patients’ progress more closely, the platform fosters a collaborative approach to diabetes management.
Mike Alvarez, Chief Executive Officer of Glooko, commented, “We are very pleased to bring this algorithm-driven, personalized innovation to diabetes patients and their healthcare teams through our partnership with Hedia. With extensive clinical data supporting Hedia’s efficacy, this solution provides an alternative for those unable to access insulin pumps, ensuring more effective management of MDI therapy. This partnership reflects Glooko’s commitment to advancing digital health tools that optimize diabetes care and help stabilize blood glucose levels through personalized, connected care.”
Lars Christian Lund, Chief Executive Officer of Hedia, also shared his enthusiasm for the collaboration, stating, “We are thrilled to be partnering with Glooko, a digital health company with an extensive clinical network. This joint offering is perfectly aligned with Hedia’s vision to improve the quality of life for people with diabetes and make the best diabetes management tools available. In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance, and we recently got MDR certified in Europe. Hedia’s Class IIb medical device designation ensures that patients and their care teams are getting the best solutions.”
Hedia is a prominent digital therapeutics company focused on improving the lives of people with insulin-dependent diabetes. The Hedia Diabetes Assistant, designed to offer personalized insulin recommendations based on an individual’s habits and inputs, takes into account important aspects of diabetes management such as blood glucose readings, insulin tracking, carb counting, activity monitoring, and blood ketone levels. With this approach, Hedia aims to simplify and optimize diabetes care.
Glooko, known for its personalized, connected care platform, serves over 4.4 million users worldwide and is deployed in more than 30 countries across 10,000+ clinical locations. The Glooko platform is a Class IIa medical device certified under the new Medical Device Regulation (MDR), offering innovative solutions that improve health outcomes for people with chronic conditions. By integrating digital therapeutics with real-time health data, Glooko helps to engage patients in their care, improve adherence, and accelerate clinical trials.
Through the Glooko-Hedia partnership, patients and healthcare providers now have access to an advanced solution that simplifies the management. By offering personalized bolus insulin dosing recommendations and improved care coordination, the platform is helping people with diabetes better manage their condition and live healthier lives.
Please find the related post
